Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713479 | 0.96 | EPAS1 (0.41) | EPAS1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL509273 | 0.88 | ALDH1A1 (0.41) | EPAS1ALDH1A1CXCR2HSD11B1CA1 | |
| SCHEMBL10204404 | 0.88 | EPAS1 (0.37) | EPAS1CXCR2HSD11B1CA1CA2 | |
| SCHEMBL18002911 | 0.84 | EPAS1 (0.35) | EPAS1CXCR2HSD11B1CA1CA2 | |
| SCHEMBL926505 | 0.84 | CA2 (0.41) | CXCR2HSD11B1CA1CA2CXCR1 | |
| SCHEMBL7241272 | 0.82 | ADORA2A (0.44) | EPAS1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL19859413 | 0.81 | DRD2 (0.42) | EPAS1ALDH1A1CXCR2HSD11B1HTR1D | |
| SCHEMBL10073222 | 0.81 | CXCR2 (0.40) | ALDH1A1CXCR2HSD11B1CA1CA2 | |
| SCHEMBL167959 | 0.80 | PPARG (0.54) | ALDH1A1MAPK1TDP1HSD11B1CA1 | |
| SCHEMBL7422254 | 0.80 | SLC7A5 (0.43) | ALDH1A1TSHRTDP1CXCR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138861-A1 | METHOD FOR CONSTRUCTING C-P BOND BY MEANS OF NICKEL-CATALYZED HIRAO REACTION | 浙江九洲药业股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-116023383-A | Synthesis method of chiral tetrahydrofurano [2,3-b ] tetrahydroquinoline derivative | 广西师范大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115894560-A | Method for constructing C-P bond through Hirao reaction catalyzed by nickel | 浙江九洲药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-105492075-B | Inhibitors of viral replication, their preparation method and their therapeutical uses | HIVIH公司 | 2019-11-12 | — | — | CN | disclosed |
| EP-2949655-B1 | REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | HOKKO CHEM IND CO (JP) | 2019-05-15 | — | — | EP | disclosed |
| CN-105906617-B | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-106866463-B | The preparation method of Ai Shadulin intermediates | 富乐马鸿凯（大连）医药有限公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-107266514-A | Method for producing E4 intermediate | 埃斯特拉私人有限责任公司 | 2017-10-20 | — | — | CN | disclosed |
| US-9707551-B2 | Reaction catalyst for cross-coupling and method for manufacturing aromatic compound | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| CN-106866463-A | The preparation method of Ai Shadulin intermediates | 大连鸿凯化工科技发展有限公司 | 2017-06-20 | — | — | CN | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6365776-B1 | FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | EPAS1 152/4885ALDH1A1 1740/4885CYP3A4 3445/4885 |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TYR, DDC, PNMT | EPAS1 1175/4885ALDH1A1 1669/4885CYP3A4 301/4885 |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | EPAS1 2517/4885ALDH1A1 2369/4885CYP3A4 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.